These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 36253003)

  • 1. Response to: Correspondence on "Quality is more important than quantity: pre-operative sarcopenia is associated with poor survival in advanced ovarian cancer" by Maccio and Madeddu.
    Kumar A; Polen-De C
    Int J Gynecol Cancer; 2022 Nov; 32(11):1494. PubMed ID: 36253003
    [No Abstract]   [Full Text] [Related]  

  • 2. Correspondence on "Quality is more important than quantity: pre-operative sarcopenia is associated with poor survival in advanced ovarian cancer" by Polen-De et al.
    Maccio A; Madeddu C
    Int J Gynecol Cancer; 2022 Nov; 32(11):1493. PubMed ID: 36253005
    [No Abstract]   [Full Text] [Related]  

  • 3. Pre-operative core muscle index in combination with hypoalbuminemia is associated with poor prognosis in advanced ovarian cancer.
    Conrad LB; Awdeh H; Acosta-Torres S; Conrad SA; Bailey AA; Miller DS; Lea JS
    J Surg Oncol; 2018 Apr; 117(5):1020-1028. PubMed ID: 29409111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of computed tomography-based sarcopenia and the prognostic value of skeletal muscle index and muscle attenuation amongst women with epithelial ovarian malignancy: A systematic review and meta-analysis.
    Tranoulis A; Kwong FLA; Lakhiani A; Georgiou D; Yap J; Balega J
    Eur J Surg Oncol; 2022 Jul; 48(7):1441-1454. PubMed ID: 35260290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psoas muscle area is not representative of total skeletal muscle area in the assessment of sarcopenia in ovarian cancer.
    Rutten IJG; Ubachs J; Kruitwagen RFPM; Beets-Tan RGH; Olde Damink SWM; Van Gorp T
    J Cachexia Sarcopenia Muscle; 2017 Aug; 8(4):630-638. PubMed ID: 28513088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients triaged to neoadjuvant chemotherapy have higher rates of sarcopenia: An opportunity for prehabilitation.
    Fadadu PP; Polen-De CL; McGree ME; Weaver AL; Moynagh MR; Takahashi N; Langstraat CL; Cliby WA; Kumar A
    Gynecol Oncol; 2021 Jan; 160(1):40-44. PubMed ID: 33109391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of muscle measurement using the standardized phase of computed tomography in patients with advanced ovarian cancer.
    Huang CY; Sun FJ; Lee J
    Nutrition; 2020 Apr; 72():110642. PubMed ID: 31986319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progressive Sarcopenia in Patients With Colorectal Cancer Predicts Survival.
    Deng CY; Lin YC; Wu JS; Cheung YC; Fan CW; Yeh KY; McMahon CJ
    AJR Am J Roentgenol; 2018 Mar; 210(3):526-532. PubMed ID: 29364725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skeletal Muscle Attenuation (Sarcopenia) Predicts Reduced Overall Survival in Patients with Advanced Epithelial Ovarian Cancer Undergoing Primary Debulking Surgery.
    Ataseven B; Luengo TG; du Bois A; Waltering KU; Traut A; Heitz F; Alesina PF; Prader S; Meier B; Schneider S; Koch JA; Walz M; Groeben HT; Nina P; Brunkhorst V; Heikaus S; Harter P
    Ann Surg Oncol; 2018 Oct; 25(11):3372-3379. PubMed ID: 30069659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sarcopenia as a predictor of survival and chemotoxicity in patients with epithelial ovarian cancer receiving platinum and taxane-based chemotherapy.
    Staley SA; Tucker K; Newton M; Ertel M; Oldan J; Doherty I; West L; Zhang Y; Gehrig PA
    Gynecol Oncol; 2020 Mar; 156(3):695-700. PubMed ID: 31928805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of sarcopenia on survival and surgical complications in ovarian cancer patients undergoing primary debulking surgery.
    Rutten IJ; Ubachs J; Kruitwagen RF; van Dijk DP; Beets-Tan RG; Massuger LF; Olde Damink SW; Van Gorp T
    Eur J Surg Oncol; 2017 Apr; 43(4):717-724. PubMed ID: 28159443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psoas as a sentinel muscle for sarcopenia: a flawed premise.
    Baracos VE
    J Cachexia Sarcopenia Muscle; 2017 Aug; 8(4):527-528. PubMed ID: 28675689
    [No Abstract]   [Full Text] [Related]  

  • 13. The impact of body composition on treatment in ovarian cancer: a current insight.
    McSharry V; Glennon K; Mullee A; Brennan D
    Expert Rev Clin Pharmacol; 2021 Sep; 14(9):1065-1074. PubMed ID: 34080491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantity and Quality of Skeletal Muscle as an Important Predictor of Clinical Outcomes in Patients with Esophageal Cancer Undergoing Esophagectomy after Neoadjuvant Chemotherapy.
    Ishida T; Makino T; Yamasaki M; Yamashita K; Tanaka K; Saito T; Yamamoto K; Takahashi T; Kurokawa Y; Motoori M; Kimura Y; Nakajima K; Eguchi H; Doki Y
    Ann Surg Oncol; 2021 Nov; 28(12):7185-7195. PubMed ID: 33876359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for surgery-related muscle quantity and muscle quality loss and their impact on outcome.
    van Wijk L; van Duinhoven S; Liem MSL; Bouman DE; Viddeleer AR; Klaase JM
    Eur J Med Res; 2021 Apr; 26(1):36. PubMed ID: 33892809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of psoas major muscle density in patients with breast cancer metastases to bone: a retrospective single-center cohort study.
    Yao H; Dohzono S; Sasaoka R; Takamatsu K; Nakamura H
    Jpn J Clin Oncol; 2022 Jan; 52(1):8-13. PubMed ID: 34642753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of measurement of skeletal muscle mass on clinical outcomes in patients with esophageal cancer undergoing esophagectomy after neoadjuvant chemotherapy.
    Ishida T; Makino T; Yamasaki M; Tanaka K; Miyazaki Y; Takahashi T; Kurokawa Y; Motoori M; Kimura Y; Nakajima K; Mori M; Doki Y
    Surgery; 2019 Dec; 166(6):1041-1047. PubMed ID: 31607486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Muscle composition measured by CT scan is a measurable predictor of overall survival in advanced ovarian cancer.
    Kumar A; Moynagh MR; Multinu F; Cliby WA; McGree ME; Weaver AL; Young PM; Bakkum-Gamez JN; Langstraat CL; Dowdy SC; Jatoi A; Mariani A
    Gynecol Oncol; 2016 Aug; 142(2):311-6. PubMed ID: 27235857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A lower psoas muscle volume was associated with a higher rate of recurrence in male clear cell renal cell carcinoma.
    Noguchi G; Kawahara T; Kobayashi K; Tsutsumi S; Ohtake S; Osaka K; Umemoto S; Nakaigawa N; Uemura H; Kishida T; Yao M
    PLoS One; 2020; 15(1):e0226581. PubMed ID: 31895931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated platelet lymphocyte ratio is a poor prognostic factor in advanced epithelial ovarian cancer.
    Chon S; Lee S; Jeong D; Lim S; Lee K; Shin J
    J Gynecol Obstet Hum Reprod; 2021 Jun; 50(6):101849. PubMed ID: 32619726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.